FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	RNEY DOCKET NO. APPLICATION NO.		
36731S-000001/US	10/786,907		
APPLICANT			
Bjarne Bogen			
FILING DATE	GROUP		
February 25, 2004	1643		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Ref. Desig.	Examiner's Initials			
1.	/LB/	Arya Biragyn et al; "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity"; Nature Biotechnology; Volume 17, March 1999, pages 253-258.		
2.		Andreas Pluckthun et. Al.; "New protein engineering approaches to multivalent and bispecific antibody fragments"; Immunotechnology, Volume 3, 1997, pages 83-105.		
3.	000000000000000000000000000000000000000	immune responses to dendritic cell-based treatment"; Cancer Immunol Immunother, Volume 51, 2002, pages 341-348.		
4.	2000000	Hsing-I Huang et. al.; "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand"; Int. J. Cancer, Volume 108, 2004, pages 696-703.		
5.	***************************************	Izu-Hsuan Huang et. al.; "Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen", Blood, Volume 96, No.12, December 2000, pages 3663-3670		
6.	000000000000000000000000000000000000000	Jitra, Kriangkum et. al.; "Bispecific and bifunctional single chain recombinant antibodies"; Biomolecular Engineering, Volume 18, 2001, pages 31-40.		
7.	восположения	Annemiek B. van Spriel et. al.; "Immunothera peutic perspective for bispecific antibodies"; Immunology today, Volume 21, No. 8, August 2000, pages 391-396.		
8.		Hennie R. Hoogenboom; "Mix and match: Building manifold binding sites"; Nature Biotechnology, Volume 15, February 1997, pages 125-226.		
9.		Shi-zhen Hu et. al.; "Minibody: A Novel Engineered Anti-Carcinoembryotic Antigen Antibody Fragment (Single-Chain Fv-CH3), Which Exhibits Rapid, High-Level Targeting of Xenograftsl"; Cancer Research, Volume 56, July 1996, pages 3055-3061.		
10.	200000000000000000000000000000000000000	Arya Biragyn et. al.; "Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by Beta- Defensin 2"; Science, Volume 298, November 2002, pages 1025-1029		
11.	00000	E. Lunde et. al.; "Troybodies and Pepbodies"; Biochemical Society Transactions, Volume 30, Part 4, 2002, pages 500-506.		
12.	000000000000000000000000000000000000000	Elin Lunde et. al.; "Troy-bodies"; Intern, Rev. Immunol., Volume 20. 2001,: Recombinant Antibodies that Target T Cell Epitopes to Antigen Presenting Cells", pages 647-673.		
13.		Adelchi Ruffini et. al.; "Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines", Haematologica, Volume 87, 2002, Pier, pages 989-1001.		

/	Lynn Bristoi/			
Examiner:		Date Considered:	10/25/2009	